all report title image
  • Published On : Dec 2022
  • Code : CMI5393
  • Industry : Medical Devices
  • Pages : 166
  • Formats :

The global platelet aggregation devices market was valued at US$ 518.7 Mn in 2021 and is forecast to reach a value of US$ 794.0 Mn by 2028 at a CAGR of 6.3% between 2022 and 2028. The global platelet aggregation devices market is experiencing strong growth owing to the increasing incidence of cardiovascular diseases (CVDs) and growing burden of bleeding disorders across the globe. Moreover, growing geriatric population and rise in demand for platelet aggregation devices worldwide is expected to boost the market growth. However, factors such as high cost of platelet aggregation devices and shortage of skilled personnel are expected to hamper growth of the global platelet aggregation devices market.

Global Platelet Aggregation Devices Market: Regional Insights

Based on geography, the global platelet aggregation devices market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.

Among regions, North America is expected to gain highest share in the market during the forecast period owing to the increasing incidence of chronic and bleeding disorders and growing geriatric population in the region, especially in the United States. For instance, platelet aggregation devices are often used to treat cardiovascular and bleeding disorders. According to the Centers for Disease Control and Prevention (CDC), around 85% of older adults in the U.S. have at least one chronic health condition, and 60% have at least two chronic conditions. This in turn is expected to increase demand for platelet aggregation devices in the region.

Asia Pacific is also expected to witness robust growth in the global platelet aggregation devices market due to the increase in prevalence of chronic diseases and growing geriatric population in the region. For instance, tumors have the ability to induce platelet aggregation which is referred as tumor cell induced platelet aggregation (TCIPA). According to data based on current trends from the cancer report by the Indian Council of Medical Research (ICMR), India’s cancer cases could increase by 12% in the next five years, with 1.5 million people projected to suffer from the non-communicable disease by 2025, up from 1.39 million in 2020.

Figure 1. Global Platelet Aggregation Devices Market Share (%), by Region, 2022

Platelet Aggregation Devices  | Coherent Market Insights

Global Platelet Aggregation Devices Market Drivers:

Increasing incidence of cardiovascular diseases (CVDs) around the world is expected to boost the growth of the platelet aggregation devices market during the forecast period. For instance, platelet aggregation devices are used for the treatment of CVDs, which in turn is expected to increase the demand for platelet aggregation devices worldwide. According to the World Health Organization (WHO), CVDs are the leading cause of global mortality and major contributor to disability, taking an estimated 17.9 million lives each year. This in turn is expected to increase demand for platelet aggregation devices around the world.

Growing burden of bleeding disorders across the globe is expected to augment growth of the global platelet aggregation devices market during the forecast period. With growing incidence of bleeding disorders, the demand for platelet aggregation devices/systems is also increasing, as they are used to diagnose bleeding disorders. Platelet aggregation test is usually performed on individuals with bleeding problems. According to the Centers for Disease Control and Prevention (CDC), there are about 3 million people nationwide who are affected by bleeding disorders. This in turn is expected to increase demand for platelet aggregation devices.

Global Platelet Aggregation Devices Market Opportunities:

Increase in demand for platelet aggregation devices worldwide is expected to provide significant growth opportunities for players in the platelet aggregation devices market. For instance, with the increase in burden of chronic and bleeding disorders, the demand for platelet aggregation devices is also increasing with a rapid pace. In March 2020, Hart Bio announced the launch of ADP MEA and TRAP-6 MEA. Both ADP MEA and TRAP-6 MEA are designed to monitor and test platelet aggregation function of patients. ADP MEA is designed for use in diagnosing platelet dysfunction or normal platelet activity in whole blood for Multiple Electrode Aggregometry.

Growing geriatric population across the world is expected to offer lucrative growth opportunities for players in the global platelet aggregation devices market. For instance, aging increases the risk of chronic diseases such as heart disease, diabetes, and cancer. Moreover, growing population of older adult patients with bleeding disorders is at the risk of age-related comorbidities. According to the World Health Organization (WHO), by 2030, one in six people in the world will be aged 60 years or over, and by 2050, the world’s population of people aged 60 years and older will double (2.1 billion). This in turn is expected to propel market growth.

CMI table icon

Platelet Aggregation Devices Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2021: US$ 518.7 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2028
Forecast Period 2022 to 2028 CAGR: 6.3% 2028 Value Projection: US$ 794.0 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Product: Systems, Reagents, and Consumables and Accessories),
  • By Application: Clinical Applications and Research Applications
  • By End User: Hospitals, Diagnostic Laboratories, and Other End Users
Companies covered:

Sysmex Corporation, WerfenLife SA, Siemens Healthineers, Sentinel Ch. SpA, Haemonetics Corporation, Chrono-Log Corporation, Bio/Data Corporation, Aggredyne Inc., F. Hoffmann-La Roche Ltd., and Helena Laboratories Corporation, among others.

Growth Drivers:
  • Increasing incidence of cardiovascular diseases (CVDs) around the world
  • Growing burden of bleeding disorders across the globe
Restraints & Challenges:
  • High cost of platelet aggregation devices
  • Shortage of skilled personnel

Global Platelet Aggregation Devices Market Trends:

Aggregation devices/systems are expected to grow over the forecast period due to factors such as technological advancements in the field of platelet aggregation devices. As these advances have reached clinical use, the demand for these devices has increased. Further future improvements and developments are also expected to help the market growth. This trend is expected to continue over the forecast period, driving the growth of the market.

Moreover, with the increase in burden of hemostasis disorders, the demand for platelet aggregation devices is also increasing with a rapid pace, worldwide, as platelet arrogation testing is essential for the diagnosis of hemostasis/bleeding disorders. Bleeding disorders are a group of conditions in which there is a problem with the body's blood clotting process. This trend is expected to continue during the forecast period, driving the growth of the market.

Global Platelet Aggregation Devices Market Restraints:

High cost of platelet aggregation devices and shortage of skilled personnel is expected to hamper growth of the global platelet aggregation devices market. For instance, although new technologies, devices, or systems are having profound impact on patients, doctors, and healthcare organizations, the medical workforce (skilled personnel) falls short as a career choice for many reasons, leading to the current shortage. This is one of the significant challenges faced by the platelet aggregation devices market, which hinders the growth of the market.

Figure 2. Global Platelet Aggregation Devices Market Share (%), by Product, 2022

Platelet Aggregation Devices  | Coherent Market Insights

Global Platelet Aggregation Devices Market Segmentation:

The global platelet aggregation devices market report is segmented into Product, Application, End User, and Geography.

Based on Product, the platelet aggregation devices market is segmented into Systems, Reagents, and Consumables and Accessories. Out of which, Systems Segment is expected to dominate the platelet aggregation devices market over the forecast period and this is attributed to the increase in adoption of platelet aggregation systems. Platelet aggregation systems (or aggregometers) can be used to determine how well platelets stick together.

Reagents Segment is also expected to witness significant growth in the near future and this is owing to the increase in use of platelet aggregation reagents. The reagents are selected on the basis of the method type on which platelet aggregometry is performed.

Based on Application, the global platelet aggregation devices market is segmented into Clinical Applications and Research Applications. Of which, Research Applications Segment is expected to dominate the market over the forecast period and this is attributed to the increase in research and development across the world. Platelet aggregation is being used in various research studies such as in toxicology and screening of novel medical preparations.

Based on End User, the market is segmented into Hospitals, Diagnostic Laboratories, and Other End Users. Out of which, Hospitals Segment is expected to dominate the market over the forecast period and this is attributed to the increase in number of surgeries. Platelet aggregation devices are used in to detect abnormalities in platelets during surgeries in hospitals.

Diagnostic Laboratories Segment is also expected to witness significant growth in the near future and this is owing to the increase in prevalence of chronic diseases worldwide.

Global Platelet Aggregation Devices Market: Key Developments

In May 2019, Haemonetics received the U.S. Food and Drug Administration (FDA) clearance in expanded use of TEG 6s Hemostasis Analyzer System in adult trauma setting for cardiovascular surgery and cardiology procedures.

In April 2019, Aggredyne Inc. received the U.S. Food and Drug Administration (FDA) approval for AggreGuide A-100 ADP Assay testing cartridge an in vitro diagnostic device used to measure various antiplatelet medications that target the platelet P2Y12 receptor.

Global Platelet Aggregation Devices Market: Key Companies Insights

The global platelet aggregation devices market is highly competitive. This is attributed to the rise in adoption of or demand for platelet aggregation devices/systems, as a result, players in the market are focusing on launching novel products in the market.

Some of the key players in the global platelet aggregation devices market are Sysmex Corporation, WerfenLife SA, Siemens Healthineers, Sentinel Ch. SpA, Haemonetics Corporation, Chrono-Log Corporation, Bio/Data Corporation, Aggredyne Inc., F. Hoffmann-La Roche Ltd., and Helena Laboratories Corporation, among others.

*Definition: Platelet function tests are a group of assays use to measure the ability of platelets to aggregate and promote clotting in a sample of blood. Thus, platelet aggregation devices are often used to treat cardiovascular and bleeding disorders.  

A platelet aggregation test is a blood test that looks at how well blood cells called platelets clump together and clot. Platelet tests check for conditions that cause too much bleeding or too much blood clotting. The test checks how well platelets, a part of blood, clump together, and cause blood to clot. Thus, platelet aggregation devices are often used to treat bleeding disorders. A variety of tests are available but there is no one test that identifies all problems with platelet function.

Market Dynamics:

Growing burden of bleeding disorders, increasing incidence of chronic diseases, growing geriatric population, and rise in demand for platelet aggregation devices across the globe are major factors expected to drive growth of the global platelet aggregation devices market.

For instance, in February 2022, Futura Surgicare launched hemostatic products under the brand Hemostax (Oxidized Regenerated Cellulose) under a new vertical, Dolphin Hemostats. Hemostax Standard is an absorbable hemostat designed to help surgeons control bleeding more efficiently.

In July 2021, Baxter International reported its Baxter Healthcare Corporation subsidiary acquired certain assets related to the PerClot Polysaccharide Hemostatic System from CryoLife, Inc. The PerClot Polysaccharide Hemostatic System is used to control bleeding during surgical procedures, including gynecologic, general, cardiovascular, and urology.

Key features of the study:

  • This report provides in-depth analysis of the global platelet aggregation devices market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022–2028), considering 2021 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global platelet aggregation devices market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Sysmex Corporation, WerfenLife SA, Siemens Healthineers, Haemonetics Corporation, Chrono-Log Corporation, Bio/Data Corporation, Aggredyne Inc., F. Hoffmann-La Roche Ltd., Sentinel Ch. SpA, and Helena Laboratories Corporation, among others.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global platelet aggregation devices market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global platelet aggregation devices market.

Detailed Segmentation:

  • Global Platelet Aggregation Devices Market, By Product:
    • Systems
    • Reagents
    • Consumables and Accessories
  • Global Platelet Aggregation Devices Market, By Application:
    • Clinical Applications
    • Research Applications
  • Global Platelet Aggregation Devices Market, By End User:
    • Hospitals
    • Diagnostic Laboratories
    • Other End Users
  • Global Platelet Aggregation Devices Market, By Geography:
    • North America
    • Europe
    • Asia-Pacific
    • Middle East and Africa
    • South America
  • Company Profiles:
    • Sysmex Corporation
    • WerfenLife SA
    • Siemens Healthineers
    • Sentinel Ch. SpA
    • Haemonetics Corporation
    • Chrono-Log Corporation
    • Bio/Data Corporation
    • Aggredyne Inc.
    • F. Hoffmann-La Roche Ltd.
    • Helena Laboratories Corporation

Frequently Asked Questions

The global platelet aggregation devices market size is estimated to be valued at US$ 549.0 Million in 2022 and is expected to exhibit a CAGR of 6.3% between 2022 and 2028.
Increasing incidence of cardiovascular diseases (CVDs) and growing burden of bleeding disorders across the globe is fueling the market.
Reagent segment is the leading product segment in the market.
High cost of platelet aggregation devices and shortage of skilled personnel are factors restraining the market.
Major players operating in the market are Sysmex Corporation, WerfenLife SA, Siemens Healthineers, Sentinel Ch. SpA, Haemonetics Corporation, Chrono-Log Corporation, Bio/Data Corporation, Aggredyne Inc., F. Hoffmann-La Roche Ltd., and Helena Laboratories Corporation, among others.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo